Identifying the Physical and Mental Healthcare Needs of Opioid Treatment Program Clients

O’Grady, Megan A.; Neighbors, Charles J.; Randrianarivony, Rina; Shapiro-Luft, Dina; Tempchin, Jacob; Perez-Cubillan, Yaberci; Collymore, David C; Martin, Keith L.; Heyward, Nyasia; Wu, Morgan; Beacham, Alexa; Greenfield, Belinda

doi:10.1080/10826084.2022.2064508

Cited by 9 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, there is a need for better linkages between mental health and addiction services sometimes referred to as 'integration' in the literature [58], and better alignment with other systems (e.g., housing sector). The need for better linkages across systems and, thus, a reduction in 'silos' has been highlighted by many other researchers for some time [59][60][61]. Family members and CBO staff in our study identified transportation needs and childcare responsibilities as impacting treatment access and retention, thus pointing to the importance of implementing free, accessible public transportation, and providing accessible childcare supports.…”

Section: Discussionmentioning

confidence: 63%

What features of drug treatment programs help, or not, with access? a qualitative study of the perspectives of family members and community-based organization staff in Atlantic Canada

Mathias,

Jackson,

Buxton

et al. 2024

Subst Abuse Treat Prev Policy

View full text Add to dashboard Cite

Background Withdrawal management and opioid agonist treatment (OAT) programs help to reduce some of the harms experienced by people who use substances (PWUS). There is literature on how features of drug treatment programs (e.g., policies and practices) are helpful, or not helpful, to PWUS when seeking access to, or in, treatment. There is, however, relatively little literature based on the perspectives of family members/family of choice of PWUS and community-based organization staff within the context of Atlantic Canada. This paper explored the perspectives of these two groups on what was helpful, or not, about drug treatment programs in Atlantic Canada in terms of supporting access to, and retention in, treatment. Methods One-on-one qualitative telephone interviews were conducted in 2020 with the two groups. Interviews focused on government-funded withdrawal management and OAT programs. Data were coded using a qualitative data management program (ATLAS.ti) and analyzed inductively for key themes/subthemes using grounded theory techniques. Results Fifteen family members/family of choice and 16 community-based organization staff members participated (n = 31). Participants spoke about features of drug treatment programs in various places, and noted features that were perceived as helpful (e.g., quick access), as well as not helpful (e.g., wait times, programs located far from where PWUS live). Some participants provided their perceptions of how PWUS felt when seeking or accessing treatment. A number of participants reported taking various actions to help support access to treatment, including providing transportation to programs. A few participants also provided suggestions for change to help support access and retention such as better alignment of mental health and addiction systems. Conclusions Participants highlighted several helpful and not helpful features of drug treatment programs in terms of supporting treatment access and retention. Previous studies with PWUS and in other places have reported similar features, some of which (e.g., wait times) have been reported for many years. Changes are needed to reduce barriers to access and retention including the changes recommended by study participants. It is critical that the voices of key groups, (including PWUS) are heard to ensure treatment programs in all places support access and retention.

show abstract

Section: Discussionmentioning

confidence: 63%

What features of drug treatment programs help, or not, with access? a qualitative study of the perspectives of family members and community-based organization staff in Atlantic Canada

Mathias,

Jackson,

Buxton

et al. 2024

Subst Abuse Treat Prev Policy

View full text Add to dashboard Cite

show abstract

“…We are delighted to see several very recent publications about OUD-PTSD comorbidity, which were available in press after the acceptance of our manuscript. [5][6][7][8][9][10] Furthermore, it can be argued that considering the prevalence of OUD-PTSD, much more work is warranted towards understanding this comorbidity or even the effect of trauma exposure on the development of OUD. In our opinion, more emphasis on probing the behavioural and neurobiological processes active in patients with OUD-PTSD could further the understanding of this illness.…”

Section: Continuing the Conversation Around Opioid Use Disorder And P...mentioning

confidence: 99%

Continuing the conversation around opioid use disorder and post-traumatic stress disorder comorbidity

Upadhyay

Verrico

Cay

et al. 2022

The Lancet Psychiatry

View full text Add to dashboard Cite

“…[7][8][9] In a pilot study aimed to evaluate geriatric conditions among MMT in comparison with a representative sample of community-dwelling older adults, the most common chronic disease of the 47 adults on MMT (mean age 58.8 years) was HTN 9 (59.6%). Likewise, in a large study among 1000 MMT patients in NY, 50% reportedly had HTN 10 . Still, that figure may be an overestimation since the authors used a systolic BP (sBP) cut-off value 130 mmHg and not the usually applied definition of HTN as a sBP of ≥140 mmHg.…”

Section: Introductionmentioning

confidence: 97%

Prevalence and Risk Factors of Hypertension among Patients with Opioid Use Disorder in Methadone Maintenance Treatment

Sason,

Adelson,

Schreiber

et al. 2023

Preprint

View full text Add to dashboard Cite

BACKGROUNDThe current prevalence of hypertension (HTN) and risk factors that characterize its occurrence during long-term methadone maintenance treatment (MMT) have not been established.METHODSHTN was defined if either systolic blood pressure (BP) ≥140 mmHg or diastolic BP ≥90 mmHg was detected twice (one week apart) among adult MMT patients. Recorded and current body mass index (BMI), BP, methadone dose and serum level, and drugs in urine were analyzed. Data on socioeconomic and addiction history characteristics were also retrieved.RESULTSHTN was detected in 103 (35.4%) of the 291 study patients (age range 26-81 years, 62 females). The HTN and non-HTN groups were comparable in sex (P=0.3), age (56.6±9.6 vs. 55.3±9.7 years,P=0.3), and duration in MMT (13.0±9.1 vs. 12.5±8.6 years,P=0.7). Age correlated linearly with duration in MMT (R=0.3,P<0.001) and with systolic BP (R=0.27,P<0.001). Patients with HTN had higher BMI values than those without HTN (28.1±5.4 vs. 25.5±5.2, respectively,P<0.001) and fewer had positive urine test findings to any substance (35.7% vs. 50.5%,P=0.01). Comparison of first methadone serum, BP, and BMI levels 11.9±5.8 years earlier increased more for the HTN group, independent of methadone dose and serum levels that lowered significantly over time. Drug abuse and older age were not associated with increased BMI and BP.CONCLUSIONWeight gain was associated with BP elevation and characterized patients who succeeded in drug abstinence during MMT.PERSPECTIVESIdentifying HTN and offering treatment for this highly prevalent life-threatening condition among older patients in MMT is recommended.

show abstract

Identifying the Physical and Mental Healthcare Needs of Opioid Treatment Program Clients

Cited by 9 publications

References 36 publications

What features of drug treatment programs help, or not, with access? a qualitative study of the perspectives of family members and community-based organization staff in Atlantic Canada

What features of drug treatment programs help, or not, with access? a qualitative study of the perspectives of family members and community-based organization staff in Atlantic Canada

Continuing the conversation around opioid use disorder and post-traumatic stress disorder comorbidity

Prevalence and Risk Factors of Hypertension among Patients with Opioid Use Disorder in Methadone Maintenance Treatment

Contact Info

Product

Resources

About